Background There are studies that suggest that some benzamide derivatives
may exert effects on heart failure; however, their molecular mechanism is not
very clear.
Objective The aim of this research was to evaluate the biological activity
of a 4-hydroxy-furanyl-benzamide derivative against heart failure translated as
area infarct.
Methods Biological activity produced by 4-hydroxy-furanyl-benzamide
derivative against heart failure was determinate using an ischemia-reperfusion
injury model. In addition, the effects exerted by the
4-hydroxy-furanyl-benzamide derivative on left ventricular pressure (LVP) was
evaluated in the absence or presence of some drugs such as yohimbine,
butaxamine, methoctramine and L-NAME using a model of rat heart isolated.
Results The results showed that 4-hydroxy-furanyl-benzamide derivative
decrease both infarct area and LVP. However, the effect produced by
4-hydroxy-furanyl-benzamide derivative on LVP was inhibited in the presence of
both methoctramine and L-NAME.
Conclusions All these data suggest that biological activity produced by
4-hydroxy-furanyl-benzamide derivative on left ventricular pressure is through
of both M2-muscarinic receptor and nitric oxide synthase enzyme
activation. It is important to mention that this phenomenon results as a
decrease of both infarct area and heart failure.